Country: Israel
Language: English
Source: Ministry of Health
URSODEOXYCHOLIC ACID
RAFA LABORATORIES LTD
A05AA02
CAPSULES
URSODEOXYCHOLIC ACID 250 MG
PER OS
Required
DR. FALK PHARMA, GERMANY
URSODEOXYCHOLIC ACID
URSODEOXYCHOLIC ACID
Treatment of chronic liver diseases Primary Biliary Cirrhosis & Primary Sclerosing Cholangitis.
2014-04-30
PATIENT LEAFLET ACCORDING TO THE PHARMACISTS‘ REGULATIONS (PREPARATIONS) – 1986 This medicine is sold with a doctor‘s prescription only URSOFALK ® CAPSULES 250 ACTIVE INGREDIENT: Each URSOFALK 250 capsule contains: 250 mg ursodeoxycholic acid. For a list of inactive ingredients, please see section 6. READ THIS ENTIRE LEAFLET CAREFULLY BEFORE USING THIS MEDICINE. This leaflet contains concise information about the medicine. If you have any further questions, please refer to your doctor or pharmacist. This medicine has been prescribed for the treatment of your illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar to yours. 1. WHAT IS THE MEDICINE INTENDED FOR? Treatment of chronic liver diseases: primary biliary cirrhosis and primary scelrosing cholangitis. THERAPEUTIC GROUP: Bile acids. 2. BEFORE TAKING THE MEDICINE DO NOT USE THE MEDICINE IF: • You are sensitive (allergic) to the active ingredient (bile acids) or to any of the additional ingredients this medicine contains (for a list of inactive ingredients, please see section 6). • Do not use if you suffer from acute inflammation of the gall bladder and/or biliary tract. • Do not use if you suffer from an obstruction of the biliary tract. • Do not use if you suffer from biliary colic (may be manifested by frequent pain/ cramps in the upper abdomen). • Do not use if you suffer from calcified gallstones. • Do not use if your gall bladder does not contract properly. SPECIAL WARNINGS REGARDING THE USE OF THIS MEDICINE • The medicine should be used under medical supervision (see also 'Tests and follow up' in section 3). • If you have suffered in the past from any of the conditions mentioned in the section 'Do not use the medicine if' - inform your doctor. • If you suffer from diarrhea during the treatment, inform the doctor immediately, as the doctor may decide to reduce the dosage of the medicine or to stop its use. • In rare cases, some of the symptoms of biliary cirrhosis (such as i Read the complete document
Ursofalk 250 -DL-Nov 2014-02 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT _URSOFALK_ _ 250 CAPSULES _ 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 capsule of Ursofalk 250 capsules contains 250 mg ursodeoxycholic acid (UDCA) as the active substance. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Capsules. Appearance: white, opaque hard gelatin capsules, capsule size 0, which contain a white compressed powder or granulate. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of chronic liver diseases Primary Biliary Cirrhosis & Primary Sclerosing Cholangitis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION There are no age restrictions on the use of Ursofalk 250 capsules. The following daily dose is recommended for the various indications: For the treatment of primary biliary cirrhosis (PBC) The daily dose depends on body weight, and ranges from 3 to 7 capsules (14 ± 2 mg UDCA per kg of body weight). For the first 3 months of treatment, Ursofalk 250 capsules should be taken in divided doses throughout the day. When the liver function parameters improve, the daily dose may be taken once daily in the evening. Body weight (kg) Ursofalk 250 capsules FIRST 3 MONTHS SUBSEQUENTLY morning midday evening evening (1 x daily) 47 – 62 1 1 1 3 63 – 78 1 1 2 4 79 – 93 1 2 2 5 94 – 109 2 2 2 6 Over 110 2 2 3 7 The capsules should be swallowed whole with some liquid. Ursofalk 250 capsules must be taken regularly. 2 The use of Ursofalk 250 capsules in PBC may be continued indefinitely. In patients with PBC, in rare cases the clinical symptoms may worsen at the beginning of treatment, e.g. the itching may increase. In this event, therapy should first be continued with one Ursofalk 250 capsule daily, and the dose then gradually increased (weekly increase of the daily dose by one capsule) until the dose indicated in the respective dosage regimen is reached again. General recommendation for PSC: 10 to 15 mg/kg/day administered in 2 to 4 divide Read the complete document